Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/20/2025 | $38.00 | Buy | B. Riley Securities |
Company maintained strong momentum to deliver another quarter of record revenue and earnings, while continuing to invest in multiple strategic growth initiatives Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three and six months ended December 31, 2024 ("Q2 FY 2025"). Q2 FY 2025 Company Highlights Net revenue increased 18.7% to a record $16.3 million in Q2 FY 2025, from $13.7 million in the second quarter of the prior fiscal year. Operating income increased to a record $2.5 million, 15.6% of net revenues and a year-over-year increase of 12.3%. Net income was $2.0 mill
Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will release its financial results for the fiscal 2025 second quarter ended December 31, 2024, on February 11, 2025 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Electromed Q2 Fiscal 2025 Webcast For tho
Electromed delivers eighth consecutive quarter of year-over-year revenue and profit growth, while continuing to invest in strategic growth initiatives Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended September 30, 2024 ("Q1 FY 2025"). Q1 FY 2025 Financial Highlights Net revenue increased 19.0% to $14.7 million in Q1 FY 2025, from $12.3 million in the first quarter of the prior fiscal year. Gross margin was 78.3% of net revenues, compared to 77.1% in the first quarter of the prior fiscal year. Operating income increased to $1.9 million or 13.2% of revenue compared to $0
B. Riley Securities initiated coverage of Electromed with a rating of Buy and set a new price target of $38.00
Company maintained strong momentum to deliver another quarter of record revenue and earnings, while continuing to invest in multiple strategic growth initiatives Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three and six months ended December 31, 2024 ("Q2 FY 2025"). Q2 FY 2025 Company Highlights Net revenue increased 18.7% to a record $16.3 million in Q2 FY 2025, from $13.7 million in the second quarter of the prior fiscal year. Operating income increased to a record $2.5 million, 15.6% of net revenues and a year-over-year increase of 12.3%. Net income was $2.0 mill
Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will release its financial results for the fiscal 2025 second quarter ended December 31, 2024, on February 11, 2025 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Electromed Q2 Fiscal 2025 Webcast For tho
Electromed delivers eighth consecutive quarter of year-over-year revenue and profit growth, while continuing to invest in strategic growth initiatives Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended September 30, 2024 ("Q1 FY 2025"). Q1 FY 2025 Financial Highlights Net revenue increased 19.0% to $14.7 million in Q1 FY 2025, from $12.3 million in the first quarter of the prior fiscal year. Gross margin was 78.3% of net revenues, compared to 77.1% in the first quarter of the prior fiscal year. Operating income increased to $1.9 million or 13.2% of revenue compared to $0
144/A - Electromed, Inc. (0001488917) (Subject)
144 - Electromed, Inc. (0001488917) (Subject)
10-Q - Electromed, Inc. (0001488917) (Filer)
4 - Electromed, Inc. (0001488917) (Issuer)
4 - Electromed, Inc. (0001488917) (Issuer)
4 - Electromed, Inc. (0001488917) (Issuer)
SC 13D/A - Electromed, Inc. (0001488917) (Subject)
SC 13G/A - Electromed, Inc. (0001488917) (Subject)
SC 13G/A - Electromed, Inc. (0001488917) (Subject)
4 - Electromed, Inc. (0001488917) (Issuer)
4 - Electromed, Inc. (0001488917) (Issuer)
4 - Electromed, Inc. (0001488917) (Issuer)
Key hire will drive the Company's market development and therapy adoption initiatives Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced the appointment of Peter Horwich as Vice President, Marketing. Mr. Horwich, an accomplished marketing veteran, brings over 20 years of experience in driving commercial growth in the Medical Technology market to Electromed. Prior to joining Electromed, Horwich directed Global Strategic Marketing for Respiratory Therapies at Abiomed (now J&J MedTech), a Medical Device manufacturer of extracorporeal membrane oxygenation (ECMO) lung recovery systems, where he was responsible for global marketing
Healthcare Executive Brings More Than 30 Years of Executive Experience and Commercial Success to Electromed Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced the appointment of Jim Cunniff as its new President and Chief Executive Officer (CEO), effective July 1, 2023. Mr. Cunniff will also join Electromed's Board of Directors. "We are pleased to announce the appointment of Jim Cunniff as president and CEO," said Lee Jones, Chair of the Board. "Jim is a proven executive with deep experience driving growth and profitability through excellence in products and services that benefit patients and support care teams. "As Kathle
Accomplished medical device leader to fill key strategic role Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that its Board of Directors has appointed Brad Nagel as the Company's Chief Financial Officer, effective November 14, 2022. Mr. Nagel brings to Electromed over fifteen years of financial leadership and strategic planning experience with Fortune 500 companies. Most recently, Mr. Nagel held the position of Divisional Chief Financial Officer of Global Lung Health and Visualization at Medtronic and was a key contributor in driving the unit's revenue growth. In that role, he served as the primary busine